{"entity":{"id":"nct07612891","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor","aka":[],"tldr":"A phase 1/2 trial of INV-6452 in ovarian cancer, endometrial cancer and HR-positive / HER2-negative breast cancer, run by Shenzhen Ionova Life Sciences Co., Ltd., now recruiting.","summary":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor is a phase 1/2 interventional study registered as NCT07612891 by Shenzhen Ionova Life Sciences Co., Ltd., with 201 participants planned, started 2025-07-04 and due to reach its primary completion in 2028-02-04. Interventions recorded: INV-6452.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07612891","url":"https://clinicaltrials.gov/study/NCT07612891"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","endometrial","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["shenzhen-ionova-life-sciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07612891","phase":"1/2","setting":"A Phase 1 and Phase 2, First-in-Human, Multi-Center, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor","sponsor":"Shenzhen Ionova Life Sciences Co., Ltd.","enrolled":201,"outcomes":[]},"route":"/trials/nct07612891/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"company":[{"id":"shenzhen-ionova-life-sciences","kind":"company","name":"Shenzhen Ionova Life Sciences","route":"/companies/shenzhen-ionova-life-sciences/"}]}}